Semaglutide, a medication used to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, according to research presented at the AASLD virtual Liver Meeting
40 GLP-1RA: Effects of Obesity and Related Health Issues: Tirzepatide and semaglutide, unlike prior weight-loss drugs, are effective and relatively safe/well-tolerated medications that improve nearly all the negative health consequences of obesity
Contact PHASE Plastic Surgery today and let us assess your suitability for GLP-1 treatment.
Dailey DL, Vance CGT, Van Gorp BJ, Johnson EM, Post AA, Chimenti RL, Vance KG, Franck C, Sault J, Yarasir E, Reisinger HS, Anderson A, Anderson J, Capelle R, Crouch A, Donatelle J, Kaster D, Kepros T, Nicklies E, Rein B, Worth R, Balinski M, Lafontant DE, Slade EJ, Jiang F, Ecklund D, Neill-Hudson T, Koepp M, Costigan M, Spencer M, Archer KR, Zimmerman BM, Bayman EO, Crofford LJ, Sluka KA
Relevant markers include malondialdehyde (MDA), 8-isoprostane, reduced glutathione (GSH), and high-sensitivity CRP
A spokesperson for the company told me it would still sell compounded weight loss medications "at a limited scale," but did not address my specific questions about pricing for the name-brand drugs
